Valley is aware of the nationwide supply disruption of IV fluid solution due to Hurricane Helene, and wants to reassure the community that steps have been taken to ensure the situation will have no negative impact on our patients and the community.
Clinical Trials
To view the clinical trials Valley currently has available, please use the search field or select a clinical specialty from the drop-down list below. Be sure to check back frequently, as we are always adding new studies.
For more information about any of our clinical trials, please email [email protected] or call 201-447-8453. (For cancer clinical trials, please call 201-634-5792.)
A081801 Alchemist
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
Principal Investigator(s): Jason W. Suh, MD
Status: Open and enrolling
A151216
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Principal Investigator(s): Jason W. Suh, MD
ACCLAIM 1
A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer
Principal Investigator(s): Eli Kirshner, MD
Status: Open and enrolling
BPM31510
A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
Principal Investigator(s): Rupa G. Juthani, MD
Status: Open and enrolling
EA5182
Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator(s): Eli Kirshner, MD
Status: Open and enrolling
OptimICE – PCR A012103
OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy
Principal Investigator(s): Eleonora Teplinsky, MD
Status: Open and enrolling
PACIFIC-9
A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy
Principal Investigator(s): Eli Kirshner, MD
Status: Open and enrolling
TROPION LUNG08
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)
Principal Investigator(s): Eli Kirshner, MD
Status: Open and enrolling